newsfilter
← Latest News
PR Newswire·

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

  • Windward Bio listed on Nasdaq on November 13, 2026, with an IPO price of $17.00 per share.
  • The stock closed at $28.50 on its first trading day, representing a 68% gain & a market capitalization of approximately $1.69 billion.
  • Qiming Venture Partners, which invested in Windward Bio's Series A in 2025 & Series B in 2026, participated in the IPO & recorded its 11th 2026 IPO.
  • Founded in 2024, Windward Bio develops ultra-long-acting antibody medicines for respiratory & dermatologic diseases such as asthma, COPD, & atopic dermatitis.
  • The company's lead program WIN378 is an anti-TSLP monoclonal antibody currently in Phase 2/3 trials for severe uncontrolled asthma (POLARIS-1) & Phase 2 trials for COPD (SIRIUS).
  • The pipeline includes WIN027, a clinical-stage bispecific antibody targeting TSLP & IL-13, licensed from Qyuns Therapeutics.
  • Windward Bio holds exclusive global rights to WIN378 excluding Greater China & certain Asian countries via a licensing agreement with Kelun-Biotech & Harbour BioMed.
  • Qiming Venture Partners manages $9.5 billion across 18 funds & has supported over 630 companies, with 290 achieving exits through IPOs or M&A.
Company
Qiming Venture Partners
Keywords
Qiming Venture Partners